+1 to JennaRN. Especially the point about "NateNeph perspective but I think this ov..." — I have seen the same in my own experience with Novo Nordisk CagriSema.
Want to share my personal experience related to Novo Nordisk CagriSema Phase 3 since I think it might help others in a similar situation.
I started my GLP-1 journey in October 2024 at 285 lbs with prediabetes and hypertension. My endocrinologist prescribed semaglutide 0.25mg to start.
Now, 14 months later: I am down 45 lbs, my labs have normalized, and I am off 2 of my 3 medications. The Novo Nordisk aspect specifically was something that made a big difference in my journey.
This community helped me every step of the way.
pat_auckland — that is really helpful context on Novo Nordisk CagriSema. Follow-up question: did you experience any side effects during this phase?
I am in a similar situation (about to start) and trying to set realistic expectations.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesTo answer anders_CPH's question specifically:
From a clinical standpoint, Novo Nordisk CagriSema Phase 3 is something I discuss with patients regularly.
The short answer: discuss this specific situation with your prescribing provider.
The longer answer involves weighing the risk-benefit ratio for your individual situation, which I am happy to elaborate on if helpful.